Reach the investors backing rounds like this
Backed by Main Sequence, Uniseed +4 more · verified emails and LinkedIn on Datapile
Dementia biotech Kinoxis raises $6.75 million with a $2.5m grant as cherry on top - Startup Daily
Kinoxis Therapeutics is a biotech company developing drugs for agitation and pain associated with dementia. The company is a spinout from Sydney University and is now based in Melbourne. This funding will support clinical trials for their drug candidates, KNX100 and KNX101, with results expected in 2027.
Dementia biotech Kinoxis raises $6.75 million with a $2.5m grant as cherry on top Startup Daily
| Sep 25, 2026 | Medcast | $5.4M | — | Australia |
| Sep 25, 2026 | RentBetter | $5.0M | — | Australia |
| Sep 23, 2026 | Heidi | $340.0M | — | Australia |
| Sep 21, 2026 | HEO | $37.0M | Series B | Australia |
You just read who funded Kinoxis Therapeutics. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.